AORT — Artivion, Inc. stock price, charts and financials

QT27Artivion, Inc.

Artivion, Inc. (NYSE: AORT) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
27.47
+0.64+2.39%
AORTQT27Artivion, Inc.·NYSE
27.47+2.39%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E107.02EPS (ttm)0.25Insider Own6.75%Shs Outstand48.54MPerf Week6.13%
Market Cap1.30BForward P/E65.84EPS next Y0.41Insider Trans-5.40%Shs Float46.07MPerf Month13.93%
Enterprise Value1.50BPEG0.22EPS next Q-Inst Own-Short Float5.42%Perf Quarter-25.12%
Income11.85MP/S2.84EPS this Y-65.10%Inst Trans-Short Ratio3.32Perf Half Y-33.62%
Sales458.69MP/B2.86EPS next Y386.57%ROA1.32%Short Interest2.50MPerf YTD-41.18%
Book/sh-P/C22.94EPS next 5Y108.08%ROE2.66%52W High49.40 -44.39%Perf Year-15.01%
Cash/sh-P/FCF101.51EPS past 3/5Y-ROIC3.00%52W Low19.62 40.03%Perf 3Y57.18%
Dividend Est.-EV/EBITDA23.13Sales past 3/5Y11.99% 11.75%Gross Margin62.94%Volatility3.46% 3.79%Perf 5Y4.15%
Dividend TTM-EV/Sales3.28EPS Y/Y TTM175.00%Oper. Margin7.76%ATR (14)1.06Perf 10Y123.77%
Dividend Ex-DateDec 09, 2015Quick Ratio2.22Sales Y/Y TTM17.74%Profit Margin2.55%RSI (14)61.92Recom2.17
Dividend Gr. 3/5Y33.89% -Current Ratio3.28EPS Q/Q-50.00%SMA206.46%Beta1.24Target Price40.50
Payout0.00%Debt/Eq0.57Sales Q/Q17.17%SMA5016.20%Rel Volume0.76Prev Close26.83
Employees1,800LT Debt/Eq0.64EarningsAug 06SMA200-25.23%Avg Volume803.77KPrice27.47
IPO DateFeb 12, 1993Option/ShortYes / YesEPS/Sales Surpr.14.29% 0.56%Net Debt/EBITDA3.11Volume614,645Change2.39%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-16-26ReiteratedCanaccord GenuityBuy$51$36
Jun-01-26ReiteratedStifel Nicolaus$55$45
Apr-10-26UpgradeLadenburg ThalmannNeutralBuy
Mar-05-26ReiteratedStifel Nicolaus$55
Dec-17-25ReiteratedCanaccord GenuityBuy$51
Nov-07-25ReiteratedOppenheimerOutperform$30$50
Aug-13-25DowngradeLadenburg ThalmannBuyNeutral
Aug-08-25ReiteratedNeedhamBuy$30$45
Oct-23-24ReiteratedJMP Securities$33
Aug-09-24ReiteratedOppenheimerOutperform$30
Latest News
Jul-28-26
Jul-23-26
Jul-20-26
Jul-19-26
Jul-01-26
Jun-30-26
Jun-29-26
Jun-26-26
Company

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue458441389354314299253276263
Cost of Goods Sold Incl. D&A170171140125111101859390
Gross Profit289270249229203198168183173
Selling, General and Administrative Excl. Other221213192209157170141143141
Research and Development333128293936242323
Other Operating Expense-10-10-150-17000
Operating Income3527396682179
Interest Expense242734251817171516
Unusual Expense
Non-Operating Income (Expense)615-12-2-3-6-3-10
Net Income Before Taxes1715-8-22-15-15-172-6
Income Taxes65694000-3
Consolidated Net Income1110-13-31-19-15-172-4
Net Income From Continuing Operations1110-13-31-19-15-172-3
Net Income1110-13-31-19-15-172-4
EPS (Recurring)0.250.22-0.32-0.75-0.48-0.38-0.440.05-0.11
EPS (Basic, Before Extraordinaries)0.250.22-0.32-0.75-0.48-0.38-0.440.05-0.11
EPS (Diluted)0.240.21-0.32-0.75-0.48-0.38-0.440.05-0.10
EBITDA656451272626203530
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio114.46217.19600.67
Price To Sales Ratio2.884.653.092.071.542.653.553.633.78
Gross Margin63.1061.2264.0164.6964.6566.2266.4066.3065.78
Operating Margin7.646.1210.031.691.912.680.796.163.42
Net Margin2.402.27-3.34-8.76-6.05-5.02-6.720.72-1.52
Shares Outstanding484542414039383735
Market Capitalization1,3192,0521,2017334857948971,002993
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$51.76$42.81$33.87$24.92$15.97 Close Price0.00M2.17M4.33M6.50M8.67MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Sale20.7044,001910,73960,259Jun 15
GREEN ANDREW MSVP, Regulatory and QualityJun 11 '26Option Exercise13.3944,001589,07890,259Jun 15
Holloway Jean FSVP, General CounselMar 04 '26Sale38.008,962340,556185,095Mar 04
Horton AmyVP, Chief Accounting OfficerMar 03 '26Sale37.7890134,036139,088Mar 04
Stanton Marshall S.SVP, Clinical & MD AffairMar 03 '26Sale37.782,14981,18060,097Mar 04
Holloway Jean FSVP, General CounselMar 03 '26Sale37.783,843145,172194,057Mar 04
Berry Lance AEVP, COO, CFO & TreasurerMar 03 '26Sale37.786,316238,591210,827Mar 04
Mackin James PPresident & CEOMar 03 '26Sale37.7817,887675,692947,275Mar 04
Davis John EChief Commercial OfficerMar 03 '26Sale37.784,573172,748230,794Mar 04
Stanton Marshall S.SVP, Clinical & MD AffairMar 02 '26Sale38.021,51357,53240,408Mar 03
Horton AmyVP, Chief Accounting OfficerMar 02 '26Sale38.0264124,374132,514Mar 03
Berry Lance AEVP, COO, CFO & TreasurerMar 02 '26Sale38.025,178196,893176,269Mar 03
Mackin James PPresident & CEOMar 02 '26Sale38.0214,911566,989848,214Mar 03
Holloway Jean FSVP, General CounselMar 02 '26Sale38.022,18383,008170,105Mar 03
Davis John EChief Commercial OfficerMar 02 '26Sale38.022,784105,861206,522Mar 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.